Work

A prognostic model for predicting overall survival in metastatic castrate-resistant prostate cancer (mCRPC) men treated with second-line chemotherapy.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.5011

Authors: Susan Halabi, Chen-Yen Lin, Eric Jay Small, Andrew J. Armstrong, Ellen B. Kaplan, Daniel Peter Petrylak, Cora N. Sternberg, Liji Shen, Stephane Oudard, Johann Sebastian De Bono, A. Oliver Sartor

Institutions: Duke University, Duke Medical Center, University of California, San Francisco, Duke Cancer Institute, Yale University, Azienda Ospedaliera San Camillo-Forlanini, Carlo Forlanini Hospital, Sanofi (France), Hôpital Européen Georges-Pompidou, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Tulane University

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2602952455

Cites:

Cited by:

Related to: 10